Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed May 16, 2022 · 10-Q · 46 days after period end · 0001493152-22-013577
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Net Income | -$462.69K | -$417.74K | -$2.59M | -$581.86K |
| EPS Diluted | — | -$0.12 | -$348.75 | -$0.89 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end
